SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE TO
Tender Offer Statement Pursuant to Section 14(d)(1) or
13(e)(1)
of the Securities Exchange Act of 1934
CNL HEALTHCARE
PROPERTIES, Inc.
(Name of Subject Company)
COMRIT INVESTMENTS 1, LIMITED PARTNERSHIP
COMRIT INVESTMENTS LTD.
(Bidders)
COMMON STOCK, $0.01 PAR VALUE PER SHARE
(Title of Class of Securities)
None or unknown
(CUSIP Number of Class of Securities)
Ziv Sapir
Comrit Investments 1, Limited Partnership
9 Ahad Ha’am Street
Tel Aviv, Israel 6129101
+ 972-3-519-9936
Copy to:
Amos W. Barclay
Holland & Hart LLP
1800 Broadway, Suite 300
Boulder, Colorado 80302
Phone: (303) 473-2700
(Name, Address, and Telephone Number of
Person Authorized to Receive Notices and
Communications on Behalf of Offeror)
| ¨ |
Check box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
| |
|
| |
Amount Previously Paid: |
| |
Form or Registration Number: |
| |
Filing Party: |
| |
Date Filed: |
| |
|
| ¨ |
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
| |
|
| |
Check the appropriate boxes below to designate any transactions to which the statement relates: |
| |
|
| x |
third party tender offer subject to Rule 14d-1. |
| ¨ |
issuer tender offer subject to Rule 13e-4. |
| ¨ |
going private transaction subject to Rule 13e-3 |
| ¨ |
amendment to Schedule 13D under Rule 13d-2 |
| |
|
| |
Check the following box if the filing is a final amendment reporting the results of the tender offer: ¨ |
| |
|
| |
If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon: |
| |
|
| ¨ |
Rule 13e-4(i) (Cross-Border Issuer
Tender Offer) |
| |
|
| ¨ |
Rule 14d-1(d) (Cross-Border Third-Party
Tender Offer) |
TENDER OFFER
This Tender Offer Statement on Schedule TO relates
to the offer (the “Offer”) by Comrit Investments 1, Limited Partnership (the “Purchaser”) to purchase up to 8,800,000
shares of common stock, par value $0.01 per share (the “Shares”), in CNL Healthcare Properties, Inc. (the “Corporation”),
the subject company, at a purchase price equal to $4.11 per Share, upon the terms and subject to the conditions set forth in the Offer
to Purchase (the “Offer to Purchase”) dated July 10, 2023 (the “Offer Date”) and the related Assignment
Form, copies of which are attached hereto as Exhibits (a)(1) and (a)(2), respectively. Any dividends paid after September 6,
2023, or such other date to which the Offer may be extended (the “Expiration Date”), by the terms of the Offer and as set
forth in the Assignment Form, would be assigned by tendering Shareholders to the Purchaser. Comrit Investments Ltd. is being named as
a bidder herein because it is deemed to control the Purchaser, but otherwise is not participating in the Offer.
Tender of Shares will include the tender of any
and all securities into which the Shares may be converted and any securities distributed with respect to the Shares from and after the
Offer Date. The Purchaser is entitled to all proceeds that are paid after the Expiration Date from or as a result of any claim, litigation,
class or derivative action brought by or for the benefit of the tendering Shareholders with respect to the transferred Shares, regardless
of when the claims asserted and such action accrued.
The Corporation reported 46,343 holders of record
as of December 31, 2022, and an aggregate of 173,960,540 shares of common stock outstanding as of May 10, 2023, according to
the Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023. The Purchaser and its affiliates
currently own 2,493,680 shares of the Corporation’s common stock, or approximately 1.4% of the common stock outstanding as of May 10,
2023. The 8,800,000 Shares subject to the Offer constitute approximately 5.05% of the outstanding shares of common stock of the Corporation
as of May 10, 2023. Consummation of the Offer, if all Shares sought are tendered, would require payment by the Purchaser of up to
$36,168,000 in aggregate purchase price, which the Purchaser intends to fund out of its available cash on hand.
The address of the Corporation’s principal executive offices
is CNL Center at City Commons, 450 South Orange Avenue, Orlando, Florida 32801, and its phone number is (407) 650-1000.
The information in the Offer to Purchase, including
all schedules and annexes thereto, is hereby expressly incorporated herein by reference in response to all the items of this Statement.
Item 12. Exhibits.
Item 13. Information Required by Schedule
13E-3.
Not applicable.
SIGNATURES
After due inquiry and to the best of my knowledge
and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: July 10, 2023
Comrit Investments 1, LP
| |
By: Comrit Investments Ltd., its General Partner |
|
| |
|
|
|
| |
By: |
/s/ Ziv Sapir |
|
| |
|
Ziv Sapir
Chief Executive Officer |
|
Comrit Investments Ltd.
| |
By: |
/s/ Ziv Sapir |
|
| |
|
Ziv Sapir
Chief Executive Officer |
|
Exhibit (a)(1)
OFFER TO PURCHASE FOR CASH 8,800,000
SHARES OF COMMON STOCK OF
CNL HEALTHCARE PROPERTIES, INC.
AT $4.11 PER SHARE
by: COMRIT INVESTMENTS 1, LIMITED PARTNERSHIP (the
“Purchaser”)
THE OFFER AND PRORATION PERIOD WILL
EXPIRE AT 11:59 P.M., EASTERN TIME, ON SEPTEMBER 6, 2023, UNLESS THE OFFER IS EXTENDED.
The Purchaser hereby seeks to acquire 8,800,000
shares of common stock, par value $0.01 per share (the “Shares”), in CNL HEALTHCARE PROPERTIES, INC. (the “Corporation”).
The Purchaser is not affiliated with the Corporation or its management. The Purchaser hereby offers to purchase 8,800,000 Shares at a
purchase price equal to $4.11 per Share, in cash, without interest, upon the terms and subject to the conditions set forth
in this document (the “Offer to Purchase”) and in the related Assignment Form as each may be supplemented or amended
from time to time (which together constitute the “Offer”). Any distributions paid after September 6, 2023, or such other
date to which this Offer may be extended (the “Expiration Date”), by the terms of the Offer and as set forth in the Assignment
Form, would be assigned by tendering Shareholders to the Purchaser. Tender of Shares will include the tender of any and all securities
into which the Shares may be converted and any securities distributed with respect to the Shares from and after July 10, 2023 (the
“Offer Date”).
The Corporation reported 46,343 holders of record
as of December 31, 2022, and reported a total of 173,960,540 shares of common stock outstanding as of March 8, 2023, and reported
the same total of 173,960,540 shares of common stock outstanding as of May 10, 2023, according to its Annual Report on Form 10-K
for the fiscal year ended December 31, 2022 (the “2022 Form 10-K”) and Quarterly Report on Form 10-Q for the
quarter ended March 31, 2023 (the “First Quarter Form 10-Q”), respectively. The Purchaser and its affiliates currently
own 2,493,680 shares of the Corporation’s common stock, or approximately 1.4% of the common stock outstanding as of May 10,
2023. The 8,800,000 Shares subject to the Offer constitute approximately 5.05% of the outstanding shares of common stock of the Corporation
as of May 10, 2023. Consummation of the Offer, if all Shares sought are tendered, would require payment by the Purchaser of up to
$36,168,000 in aggregate purchase price, which the Purchaser intends to fund out of its available cash on hand.
Holders of Shares (“Shareholders”)
are urged to consider the following factors:
| · | Shareholders who tender their Shares will give
up the opportunity to participate in any future benefits from the ownership of Shares, including potential future distributions by the
Corporation from property operations or dispositions (including as a result of any long-term strategic alternatives the Corporation may
be considering), and the purchase price per Share payable to a tendering Shareholder by the Purchaser may be less than the total amount
which might otherwise be received by the Shareholder with respect to the Share from the Corporation. |
| · | The Purchaser is making the Offer for investment
purposes and with the intention of making a profit from the ownership of the Shares. In establishing the purchase price of $4.11 per Share,
the Purchaser is motivated to establish the lowest price which might be acceptable to Shareholders consistent with the Purchaser’s
objectives. There is no public market for the Shares, and neither the Shareholders nor the Purchaser have any accurate means for determining
the actual present value of the Shares. Although there can be no certainty as to the actual present value of the Shares, the Corporation
established an estimated net asset value per Share (the “Estimated Per Share NAV”) of $6.92 on March 8, 2023, representing
the Corporation’s Estimated Per Share NAV as of December 31, 2022, according to its Current Report on Form 8-K filed with
the Commission on March 9, 2023 (the “NAV Announcement”). Shareholders should consult the Corporation’s public
filings pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for any such updates, which are
available at www.sec.gov. In the event that a Shareholder wishes to withdraw its tender of Shares as a result of such update, a withdrawal
of tender may be effected pursuant to Section 4 – Withdrawal Rights below. For the period between March 6, 2023
and June 5, 2023, CTT Auctions, an affiliate of CTT, reported secondary market trading prices ranging from $4.50 to $5.00 for shares
of the Corporation’s common stock. It should be noted, however, that CTT Auctions is only one of multiple trading platforms for
non-traded REITs and, therefore, that its secondary market trading information may be limited. Additionally, the Corporation reported
that during the year ended December 31, 2022, there were approximately 936,000 shares of the Corporation's common stock transferred
between investors at an average sales price of approximately $4.77 per share, according to the 2022 Form 10-K. The Corporation also
reported that during the three months ended March 31, 2023, there were approximately 332,000 shares of the Corporation’s common
stock transferred between investors at an average sales price of approximately $5.37 per share, according to the First Quarter Form 10-Q.
Further, the Purchaser has not made an independent appraisal of the Shares or the Corporation’s properties in connection with the
Offer and is not qualified to appraise real estate. Additionally, there can be no assurance as to the timing or amount of any future Corporation
distributions, and there cannot be any assurance that the Purchaser’s estimate accurately reflects an approximate value of the Shares
or that the actual amounts which may be realized by holders for the Shares may not vary substantially from this estimate. |
| · | Central Trade and Transfer, LLC, an affiliate
of Orchard Securities, LLC, Member FINRA/SIPC (“CTT”), who will facilitate the settlement of and payment for the tendered
Shares in conjunction with Corporation’s transfer agent, is independent of the Purchaser. However, CTT is also not acting on behalf
of the Shareholders and owes no duty to the Shareholders, fiduciary or otherwise, to advise them of their rights under this Offer. Further,
neither CTT nor the Purchaser has any rights with respect to the Shares prior to the Expiration Date and acceptance by the Purchaser for
payment. Also, by tendering your Shares, you are agreeing to arbitrate any disputes that may arise between you and any other party related
to the Offer, to subject yourself to personal jurisdiction
in Maryland, and that the prevailing party in any such action will be entitled to recover attorney fees and costs. See Section 15
– Miscellaneous for further details. |
| · | The Purchaser may accept only a portion of the
Shares tendered by a Shareholder if a total of more than 8,800,000 Shares are tendered. |
| · | THE OFFER TO PURCHASE IS NOT CONDITIONED UPON
ANY MINIMUM NUMBER OF SHARES BEING TENDERED. IF MORE THAN 8,800,000 SHARES ARE VALIDLY TENDERED AND NOT WITHDRAWN, THE PURCHASER WILL
ACCEPT FOR PURCHASE 8,800,000 SHARES FROM TENDERING SHAREHOLDERS ON A PRO RATA BASIS, SUBJECT TO THE TERMS AND CONDITIONS HEREIN. A SHAREHOLDER
MAY TENDER ANY OR ALL SHARES OWNED BY SUCH SHAREHOLDER. |
The Purchaser expressly reserves the right, in
its sole discretion, at any time and from time to time, (i) to extend the period of time during which the Offer is open and thereby
delay acceptance for payment of, and the payment for, any Shares, subject to the restriction below, (ii) upon the occurrence of any
of the conditions specified in Section 12 – Conditions of the Offer below and prior to the Expiration Date, to terminate
the Offer and not accept for payment any Shares, and (iii) to amend the Offer in any respect prior to the Expiration Date. Notice
of any such extension, termination, or amendment will promptly be disseminated to Shareholders in a manner reasonably designed to inform
Shareholders of such change in compliance with Rule 14d-4(d)(1) under the Exchange Act. In the case of an extension of the Offer,
such extension will be followed by a press release or public announcement which will be issued no later than 9:00 a.m., Eastern Time,
on the next business day after the scheduled Expiration Date, in accordance with Rule 14e-1(d) under the Exchange Act.
July 10, 2023
IMPORTANT
Any Shareholder desiring to tender any or all
of such Shareholder’s Shares should complete and sign the Assignment Form in accordance with the instructions in the Assignment
Form and mail the Assignment Form and any other required documents to the Purchaser at the address listed below. If your Shares
are held in a custodial or brokerage account, you must mail your completed Assignment Form and any other required documents to your
broker or financial advisor instead of the Purchaser. If you have any questions regarding this process, please contact the Purchaser at
the contact information listed below.
365 S. Garden Grove Lane, Suite 100
Pleasant Grove, Utah 84062
Telephone: 1-800-327-9990
E-Mail Address: offer@cttauctions.com
Attn: Comrit Investments 1, Limited Partnership
Questions or requests for assistance or additional
copies of this Offer to Purchase or the Assignment Form may be directed to CTT at 1-800-327-9990. However, CTT is not acting
on behalf of the Shareholders and owes no duty to the Shareholders, fiduciary or otherwise, to advise them of their rights under this
Offer.
NO PERSON HAS BEEN AUTHORIZED TO MAKE ANY RECOMMENDATION
OR ANY REPRESENTATION ON BEHALF OF THE PURCHASER OR TO PROVIDE ANY INFORMATION OTHER THAN AS CONTAINED HEREIN OR IN THE ASSIGNMENT FORM.
NO SUCH RECOMMENDATION, INFORMATION OR REPRESENTATION MAY BE RELIED UPON AS HAVING BEEN AUTHORIZED.
The Corporation is subject to the information
and reporting requirements of the Exchange Act and in accordance therewith is required to file reports and other information with the
Commission relating to its business, financial condition and other matters. Such reports and other information are available on the Commission’s
electronic data gathering and retrieval (“EDGAR”) system at its internet web site at www.sec.gov.
The Purchaser and Comrit Investments Ltd., the
general partner of Purchaser, have filed with the Commission a Tender Offer Statement on Schedule TO (including exhibits) pursuant to
Rule 14d-3 of the General Rules and Regulations under the Exchange Act, furnishing certain additional information with respect
to the Offer. Such statement and any amendments thereto, including exhibits, may be inspected using the Commission’s EDGAR system.
TABLE OF CONTENTS
| | |
Page |
| SUMMARY TERM SHEET | |
4 |
| INTRODUCTION | |
7 |
| TENDER OFFER | |
9 |
| Section 1. Terms of the Offer | |
9 |
| Section 2. Acceptance for Payment and Payment for Shares; Proration. | |
9 |
| Section 3. Procedures for Tendering Shares. | |
10 |
| Section 4. Withdrawal Rights. | |
10 |
| Section 5. Extension of Tender Period; Termination; Amendment. | |
11 |
| Section 6. Material Federal Income Tax Consequences. | |
11 |
| Section 7. Effects of the Offer. | |
12 |
| Section 8. Future Plans. | |
12 |
| Section 9. The Business of the Corporation. | |
12 |
| Section 10. Certain Information Concerning the Purchaser. | |
12 |
| Section 11. Source of Funds. | |
13 |
| Section 12. Conditions of the Offer. | |
13 |
| Section 13. Certain Legal Matters. | |
14 |
| Section 14. Fees and Expenses. | |
15 |
| Section 15. Miscellaneous. | |
15 |
| SCHEDULE I | |
16 |
SUMMARY TERM SHEET
The Purchaser is offering to purchase up to 8,800,000
Shares for $4.11 per Share in cash. The following are some of the questions that you, as a Shareholder of the Corporation, may have and
answers to those questions. The information in this Summary is not complete, and the Purchaser urges you to carefully read the pages following
the Summary and the accompanying Assignment Form.
WHO IS OFFERING TO BUY MY SECURITIES?
The offer to purchase your Shares is being made
by: Comrit Investments 1, Limited Partnership, a Cayman Islands Exempted Limited Partnership. The Purchaser is a real estate investment
fund. Comrit Investments Ltd., a limited liability private company organized under the laws of the State of Israel, is the general partner
of the Purchaser and is identified as a co-bidder with the Purchaser on the Tender Offer Statement on Schedule TO Filed with the Commission
in connection with the Offer. The Purchaser is not affiliated with the Corporation or its management.
WHAT ARE THE CLASSES AND AMOUNTS OF SECURITIES
SOUGHT IN THE OFFER?
The Purchaser is seeking to purchase up to 8,800,000
Shares of common stock in the Corporation.
HOW MUCH ARE YOU OFFERING TO PAY AND WHAT IS THE
FORM OF PAYMENT?
The Purchaser is offering to pay $4.11 per Share,
net to you in cash. Any distributions paid after the Expiration Date would, by the terms of the Offer and as set forth in the Assignment
Form, be assigned by tendering Shareholders to the Purchaser. If you tender your Shares to the Purchaser in the Offer, you will not have
to pay brokerage fees or similar expenses.
DO YOU HAVE THE FINANCIAL RESOURCES TO MAKE PAYMENT?
If the total amount of Shares sought is purchased,
the Purchaser’s capital commitment will be approximately $36,168,000. The Purchaser currently has sufficient funded capital to fund
all of its commitments under this Offer and any other ongoing tender offers the Purchaser is currently conducting.
IS THE FINANCIAL CONDITION OF THE BIDDERS RELEVANT
TO MY DECISION ON WHETHER TO TENDER IN THE OFFER?
Because this is a cash offer that is not conditioned
on financing being available, and the Purchaser has more than adequate resources and no intention to take control of the Corporation,
the Purchaser does not believe that additional information concerning the Purchaser’s financial condition is relevant to your decision.
HOW LONG DO I HAVE TO DECIDE WHETHER TO TENDER
IN THE OFFER?
You will have at least until 11:59 p.m., Eastern
Time, on September 6, 2023, to decide whether to tender your Shares in the Offer.
WILL ALL OF THE SHARES I TENDER BE ACCEPTED BY
THE PURCHASER?
The Purchaser desires to purchase up to 8,800,000
Shares. If the number of Shares validly tendered and not properly withdrawn on or prior to the Expiration Date is less than or equal to
8,800,000, the Purchaser will purchase all Shares so tendered and not withdrawn, upon the terms and subject to the conditions of the Offer.
However, if more than 8,800,000 Shares are so tendered and not withdrawn, the Purchaser will accept for payment and pay for 8,800,000
Shares so tendered, pro rata according to the number of Shares so tendered, adjusted by rounding down to the nearest whole number of Shares
tendered by each Shareholder to avoid purchases of fractional Shares, as appropriate. See Section 2 – Acceptance for Payment
and Payment for Shares; Proration and Section 4 – Withdrawal Rights below.
CAN THE OFFER BE EXTENDED AND UNDER WHAT CIRCUMSTANCES?
The Offer can be extended in the Purchaser’s
discretion.
HOW WILL I BE NOTIFIED IF THE OFFER IS EXTENDED?
If the Purchaser extends the Offer, it will make
a public announcement of the extension, not later than 9:00 a.m., Eastern Time, on the business day after the day on which the Offer was
scheduled to expire. Any public announcement of the extension will be made publicly available on the Commission’s website using
the EDGAR database, or you can check CTT’s website at www.cttauctions.com/offerdisclosures to see if the Offer has been extended.
WHAT ARE THE MOST SIGNIFICANT CONDITIONS TO THE
OFFER?
There are no conditions to the Offer based on
a minimum number of Shares tendered, the availability of financing, or the success of the Offer. However, the Purchaser may not be obligated
to purchase any Shares if certain conditions occur, such as legal or government actions which would prohibit the purchase. Furthermore,
the Purchaser is not obligated to purchase any Shares which are validly tendered if, among other things, there is a material adverse change
in the Corporation or its business. Please see the discussion in Section 12 – Conditions of the Offer below for a description
of all conditions. Further, by tendering your Shares, you are agreeing to arbitrate any disputes related to the Offer that may arise between
you and the Purchaser or its affiliates, to subject yourself to personal jurisdiction in Maryland, and that the prevailing party in any
such action will be entitled to recover attorney fees and costs. See Section 15 – Miscellaneous for further details.
WHEN WILL YOU PAY ME FOR THE SHARES I TENDER?
Upon the expiration of the Offer and the Purchaser’s
acceptance of the Shares you tender, the Purchaser will pay you upon confirmation that the Shares have been transferred to the Purchaser.
The Purchaser intends to pay for all validly tendered Shares within three business days following the completion of the Offer, subject
to any extensions of such time period that may be necessary due to the settlement practices of non-traded REITs, some of which are outside
the Purchaser’s control. See Section 2 – Acceptance for Payment and Payment for Shares; Proration for further
details.
HOW DO I TENDER MY SHARES?
To tender your Shares, you must deliver a completed
Assignment Form to the Purchaser at: 365 S. Garden Grove Lane, Suite 100, Pleasant Grove, Utah 84062, Attn: Comrit Investments
1, Limited Partnership (Telephone: 801-553-1031; Facsimile Transmission: 626-283-5370; Email: offer@cttauctions.com), no later than the
time the Offer expires.
UNTIL WHAT TIME CAN I WITHDRAW PREVIOUSLY TENDERED
SHARES?
Shareholders who tender their Shares in response
to the Offer will have the right to withdraw their tendered Shares at any time prior to 11:59 p.m. Eastern Time on September 6,
2023. Additionally, tenders of Shares may be withdrawn during the period in which the Offer is open. Additionally, tenders of Shares may
be withdrawn at any time after September 8, 2023, the date that is sixty (60) days from the date of this Offer to Purchase, including
with respect to any tendered Shares for which the Purchaser has not completed payment by such date.
HOW DO I WITHDRAW PREVIOUSLY TENDERED SHARES?
To withdraw Shares, you must deliver to CTT a
written or facsimile transmission notice of withdrawal identifying the name of the person who tendered Shares to be withdrawn, signed
by the same persons and in the same manner as the Assignment Form tendering the Shares, prior to the Expiration Date. Tenders
of Shares may be withdrawn during the period in which the Offer is open. Additionally, tenders of Shares may be withdrawn at any time
after September 8, 2023, the date that is sixty (60) days from the date of this Offer to Purchase, including with respect to any
tendered Shares for which the Purchaser has not completed payment by such date.
WHAT DOES THE CORPORATION THINK OF THE OFFER?
The Purchaser has not sought the approval or disapproval
of the Corporation. The Corporation may be expected to respond with the Corporation’s position on this Offer within two weeks from
the date hereof.
WILL THE CORPORATION CONTINUE AS A PUBLIC COMPANY?
Yes. The Corporation reported 46,343 holders of
its outstanding common stock as of December 31, 2022. It is not possible for this Offer to reduce the number of shareholders below
300 (the point at which a company may cease to be public).
IF I DECIDE NOT TO TENDER, HOW WILL THE OFFER
AFFECT MY SHARES?
Shares held by non-tendering Shareholders will
not be affected by the completion of the Offer.
WHAT ARE THE PURCHASER’S FUTURE INTENTIONS
CONCERNING THE CORPORATION?
The Purchaser has no present intention to seek
control of the Corporation or to change the management or operations of the Corporation. The Purchaser does not have any present intention
to take action in connection with the liquidation of the Corporation or with any extraordinary transaction concerning the Corporation
or its assets. The Purchaser will have rights as a shareholder to vote on all matters subject to a shareholder vote. The Purchaser will
be subject to the ownership limitation of 9.8% set forth in the Corporation’s charter.
WHAT IS THE MARKET VALUE OF MY SHARES?
The Shares do not have a readily ascertainable
market value, and neither the Shareholders nor the Purchaser has any accurate means for determining the actual present value of the Shares.
According to the Corporation, “There is no established public trading market for our common stock. Therefore, there is a risk that
a stockholder may not be able to sell shares at a time or price acceptable to the stockholder, or at all. Unless and until our shares
are listed on a national securities exchange, it is not expected that a public market for the shares will develop” (2022 Form 10-K).
Additionally, effective July 11, 2018, the Corporation suspended its distribution reinvestment plan and its stock redemption plan
(2022 Form 10-K).
The Purchaser commenced a tender offer for 8,800,000
shares of the Corporation’s common stock on March 13, 2023 at an offer price of $4.36 per share (the “March 2023
Tender Offer”), which ultimately resulted in the purchase by the Purchaser of approximately 945,804 shares. The Corporation’s
most recently disclosed Estimated Per Share NAV at the time of commencement of the March 2023 Tender Offer was $6.92 per share. Previously,
the Purchaser commenced a tender offer for 8,900,000 shares of the Corporation’s common stock on March 3, 2022 at an offer
price of $4.66 per share (the “March 2022 Tender Offer”), which ultimately resulted in the purchase by the Purchaser
of approximately 575,710 shares. The Corporation’s most recently disclosed Estimated Per Share NAV at the time of commencement of
the March 2022 Tender Offer was $7.38 per share.
Although there can be no certainty as to the actual
present value of the Shares, the Corporation established an Estimated Per Share NAV of $6.92 on March 8, 2023, representing the Corporation’s
Estimated Per Share NAV as of December 31, 2022, according to the NAV Announcement. Shareholders should consult the Corporation’s
public filings pursuant to the Exchange Act for any such updates, which are available at www.sec.gov. In the event that a Shareholder
wishes to withdraw its tender of Shares as a result of such update, a withdrawal of tender may be effected pursuant to Section 4
– Withdrawal Rights below.
For the period between March 6, 2023 and
June 5, 2023, CTT Auctions reported secondary market trading prices ranging from $4.50 to $5.00 for shares of the Corporation’s
common stock. It should be noted, however, that CTT Auctions is only one of multiple trading platforms for non-traded REITs and, therefore,
that its secondary market trading information may be limited. Additionally, the Corporation reported that during the year ended December 31,
2022, there were approximately 936,000 shares of the Corporation's common stock transferred between investors at an average sales price
of approximately $4.77 per share (2022 Form 10-K). The Corporation also reported that during the three months ended March 31,
2023, there were approximately 332,000 shares of the Corporation’s common stock transferred between investors at an average sales
price of approximately $5.37 per share (First Quarter Form 10-Q). Further, the Purchaser has not made an independent appraisal of
the Shares or the Corporation’s properties in connection with the Offer and is not qualified to appraise real estate. Accordingly,
there can be no assurance that the Purchaser’s estimate accurately reflects an approximate value of the Shares or that the actual
amounts which may be realized by Shareholders for the Shares may not vary substantially from that estimate.
TO WHOM CAN I TALK IF I HAVE QUESTIONS ABOUT
THE TENDER OFFER?
You can call CTT, toll-free, at 800-327-9990.
However, CTT is not acting on behalf of the Shareholders and owes no duty to the Shareholders, fiduciary or otherwise, to advise them
of their rights under this Offer.
To the Shareholders of CNL HEALTHCARE PROPERTIES, INC.:
INTRODUCTION
The Purchaser hereby offers
to purchase 8,800,000 Shares at a purchase price of $4.11 per Share (“Offer Price”), in cash, without interest, upon the terms
and subject to the conditions set forth in this Offer. Shareholders who tender their Shares will not be obligated to pay any Corporation
transfer fees, or any other fees, expenses or commissions in connection with the tender of Shares. The Purchaser will pay all such costs
and all charges and expenses of CTT and its affiliates. For further information concerning the Purchaser, see Section 11 below and
Schedule I hereto. The Purchaser is not affiliated with the Corporation or the Corporation’s management. The address of the Corporation’s
principal executive offices is CNL Center at City Commons, 450 South Orange Avenue, Orlando, Florida 32801, and its phone number is (407)
650-1000.
Establishment of the Offer Price
The Purchaser has set the
Offer Price at $4.11 per Share. In determining the Offer Price, the Purchaser analyzed a number of quantitative and qualitative factors,
including: (i) the lack of a secondary market for resales of the Shares and the resulting lack of liquidity of an investment in the
Corporation; (ii) the estimated value of the Corporation’s real estate assets; (iii) the costs to the Purchaser associated
with acquiring the Shares; and (iv) the Purchaser’s objective to profit from the Offer.
Based on disclosure in the
2022 Form 10-K, no established trading market for the Shares currently exists. Additionally, effective July 11, 2018, the Corporation
suspended its distribution reinvestment plan and its stock redemption plan (2022 Form 10-K). The lack of any public market for the
sale of Shares means that Shareholders have limited alternatives if they seek to sell their Shares. As a result of such limited alternatives
for Shareholders, the Purchaser may not need to offer as high a price for the Shares as it would otherwise. On the other hand, the Purchaser
takes a greater risk in establishing a purchase price as there is no prevailing market price to be used for reference and the Purchaser
itself will have limited liquidity for the Shares upon consummation of the purchase. Please see the discussion of market prices above
under “WHAT IS THE MARKET VALUE OF MY SHARES?”.
The Purchaser is offering
to purchase Shares which are an illiquid investment and is not offering to purchase the Corporation’s underlying assets. Although
there can be no certainty as to the actual present value of the Shares, the Corporation established an Estimated Per Share NAV of $6.92
on March 8, 2023, representing the Corporation’s Estimated Per Share NAV as of December 31, 2022, according to the NAV
Announcement. Shareholders should consult the Corporation’s public filings pursuant to the Exchange Act for any such updates, which
are available at www.sec.gov. In the event that a Shareholder wishes to withdraw its tender of Shares as a result of such update, a withdrawal
of tender may be effected pursuant to Section 4 – Withdrawal Rights below. For the period between March 6, 2023
and June 5, 2023, CTT Auctions reported secondary market trading prices ranging from $4.50 to $5.00 for shares of the Corporation’s
common stock. It should be noted, however, that CTT Auctions is only one of multiple trading platforms for non-traded REITs and, therefore,
that its secondary market trading information may be limited. Additionally, the Corporation reported that during the year ended December 31,
2022, there were approximately 936,000 shares of the Corporation's common stock transferred between investors at an average sales price
of approximately $4.77 per share (2022 Form 10-K). The Corporation also reported that during the three months ended March 31,
2023, there were approximately 332,000 shares of the Corporation’s common stock transferred between investors at an average sales
price of approximately $5.37 per share (First Quarter Form 10-Q).
In establishing the Offer
Price of $4.11 per Share, the Purchaser is motivated to establish the lowest price which might be acceptable to Shareholders consistent
with the Purchaser’s objectives. No independent person has been retained to evaluate or render any opinion with respect to the fairness
of the Offer Price and no representation is made by the Purchaser or any affiliate of the Purchaser as to such fairness. Other measures
of the value of the Shares may be relevant to Shareholders. Shareholders are urged to consider carefully all of the information contained
herein and consult with their own advisers, tax, financial or otherwise, in evaluating the terms of the Offer before deciding whether
to tender Shares.
The Offer is not made with
any current view toward or plan or purpose of acquiring Shares in a series of successive and periodic offers. Nevertheless, the Purchaser
reserves the right to gauge the response to this solicitation, and, if not successful in purchasing Shares pursuant to this Offer, may
consider future offers. The Purchaser regularly considers and evaluates potential investments in the United States real estate market,
and in non-traded REITs specifically. Factors affecting the Purchaser’s future interest in acquiring additional shares of common
stock include, but are not limited to, the relative success of the current Offer, any increase or decrease in the availability of capital
for investment by the Purchaser, the current diversification and performance of the Purchaser’s portfolio of real estate interests,
the development of any public market in the Shares or actions by unrelated parties to tender for or purchase Shares, the status of and
changes and trends in the Corporation’s operations, announcement of pending property sales and the proposed terms of sales, and
local and national real estate and financial market developments and trends.
General Background Information
Certain information contained
in this Offer to Purchase which relates to, or represents, statements made by the Corporation or its management, has been derived from
information provided in reports filed by the Corporation with the Commission. Tendering Shareholders will not be obligated to pay transfer
fees, brokerage fees, or commissions on the sale of the Shares to the Purchaser pursuant to the Offer. The Purchaser will pay all charges
and expenses incurred in connection with the Offer. The Purchaser desires to purchase up to 8,800,000 Shares. If the number of Shares
validly tendered and not properly withdrawn on or prior to the Expiration Date is less than or equal to 8,800,000, the Purchaser will
purchase all Shares so tendered and not withdrawn, upon the terms and subject to the conditions of the Offer. However, if more than 8,800,000
Shares are so tendered and not withdrawn, the Purchaser will accept for payment, and pay for, 8,800,000 Shares so tendered, pro rata according
to the number of Shares so tendered, adjusted by rounding down to the nearest whole number of Shares tendered by each Shareholder to avoid
purchases of fractional Shares, as appropriate. See Section 2 – Acceptance for Payment and Payment for Shares; Proration
and Section 4 – Withdrawal Rights.
The Purchaser will pay certain
fees and expenses to its affiliates, and to CTT and CTT’s affiliates, for certain services provided in connection with the Offer.
For more information about these fees and expenses, see Section 14 – Fees and Expenses.
If, prior to the
Expiration Date, the Purchaser increases the consideration offered to Shareholders pursuant to the Offer, such increased consideration
will be paid with respect to all Shares that are purchased pursuant to the Offer, whether or not such Shares were tendered prior to such
increase in consideration. Shareholders are urged to read this Offer to Purchase and the accompanying Assignment Form carefully
before deciding whether to tender their Shares.
TENDER OFFER
Section 1. Terms of the Offer. Upon
the terms and subject to the conditions of the Offer, the Purchaser will accept for payment and pay for Shares validly tendered on or
prior to the Expiration Date and not withdrawn in accordance with Section 4 – Withdrawal Rights of this Offer to Purchase.
The term “Expiration Date” shall mean 11:59 p.m., Eastern Time, on September 6, 2023, unless and until the Purchaser
shall have extended the period of time for which the Offer is open, in which event the term “Expiration Date” shall mean the
latest time and date on which the Offer, as so extended by the Purchaser, shall expire. The Offer is conditioned on satisfaction of certain
conditions. See Section 12 – Conditions of the Offer, which sets forth in full the conditions of the Offer. The Purchaser
reserves the right (but shall not be obligated), in its sole discretion and for any reason, to waive any or all of such conditions. If,
by the Expiration Date, any or all of such conditions have not been satisfied or waived, the Purchaser reserves the right (but shall not
be obligated) to (i) decline to purchase any of the Shares tendered, terminate the Offer and return all tendered Shares to tendering
Shareholders, (ii) waive all the unsatisfied conditions and, subject to complying with applicable rules and regulations of the
Commission, purchase all Shares validly tendered, (iii) extend the Offer and, subject to the right of Shareholders to withdraw Shares,
retain the Shares that have been tendered during the period or periods for which the Offer is extended or (iv) amend the Offer. Notwithstanding
the foregoing, upon the expiration of the Offer, subject to any extensions of such time period that may be necessary due to the settlement
practices of non-traded REITs, some of which are outside the Purchaser’s control, the Purchaser intends to pay for all validly tendered
Shares within three business days following the completion of the Offer, and the Purchaser does not intend to imply that the foregoing
rights of the Purchaser would permit the Purchaser to delay payment for validly tendered Shares following expiration. See Section 2
– Acceptance for Payment and Payment for Shares; Proration for further details.
The Purchaser does not anticipate and has no
reason to believe that any condition or event will occur that would prevent the Purchaser from purchasing tendered Shares as offered herein.
Further, by tendering your Shares, you are agreeing to arbitrate any disputes related to the Offer that may arise between you and the
Purchaser or its affiliates, to subject yourself to personal jurisdiction in Maryland, and that the prevailing party in any such action
will be entitled to recover attorney fees and costs. However, by so doing, you are not waiving any party’s compliance with, or any
of your rights under, the federal securities laws or any rule or regulation promulgated thereunder. See Section 15 – Miscellaneous
for further details.
Section 2. Acceptance for Payment and
Payment for Shares; Proration. Upon the terms and subject to the conditions of the Offer (including, if the Offer is extended or amended,
the terms and conditions of any extension or amendment), the Purchaser intends to accept for payment, and pay for, Shares validly tendered
and not withdrawn in accordance with Section 4 – Withdrawal Rights, within three business days following the completion
of the Offer, subject to any extensions of such time period that may be necessary due to the settlement practices of non-traded REITs,
some of which are outside the Purchaser’s control. Specifically, the Purchaser will mail checks to Shareholders within three business
days from the time it receives confirmation from the Corporation’s transfer agent that the Shares have been recorded as transferred
to the Purchaser in connection with the Offer. While the actions of the Corporation’s transfer agent are outside the Purchaser’s
control, the Purchaser expects that the transfer agent will provide such confirmation following Comrit’s and CTT’s collection
and delivery of validly tendered Assignment Forms after attachment of Medallion signatures and matching of tenders to validly delivered
signatures by Shareholders. The Purchaser is unaffiliated with the Corporation and its transfer agent, has no control over the Corporation
or its transfer agent and, therefore, has no ability to predict or estimate the time period that the Corporation or its transfer agent
may require to complete such confirmations in this Offer. In the March 2023 Tender Offer, however, such confirmations were provided
by the Corporation's transfer agent within seven days of the expiration of the March 2023 Tender Offer. Based only on that information,
and subject to the Purchaser's inability to control the Corporation or its transfer agent, the Purchaser anticipates that such confirmations
would proceed on a similar timeline for this Offer. In all cases, payment for Shares purchased pursuant to the Offer will be made only
after timely receipt by CTT of a properly completed and duly executed Assignment Form (or facsimile thereof) and any other documents
required by the Assignment Form. The Purchaser desires to purchase up to 8,800,000 Shares. If the number of Shares validly tendered and
not properly withdrawn on or prior to the Expiration Date is less than or equal to 8,800,000, the Purchaser will purchase all Shares so
tendered and not withdrawn, upon the terms and subject to the conditions of the Offer. However, if more than 8,800,000 Shares are so tendered
and not withdrawn, the Purchaser will accept for payment and pay for 8,800,000 Shares so tendered, pro rata according to the number of
Shares so tendered, adjusted by rounding down to the nearest whole number of Shares tendered by each Shareholder to avoid purchases of
fractional Shares, as appropriate.
In the event that proration is required, because
of the difficulty of immediately determining the precise number of Shares to be accepted, the Purchaser will announce the final results
of proration promptly following the Expiration Date. The Purchaser will not pay for any Shares tendered until after the final proration
factor has been determined, but will pay for Shares tendered promptly following the Expiration Date.
For purposes of the Offer, the Purchaser shall be deemed to have accepted
for payment (and thereby purchased) tendered Shares when, as and if the Purchaser gives oral or written notice to CTT of the Purchaser’s
acceptance for payment of such Shares pursuant to the Offer. Upon the terms and subject to the conditions of the Offer, payment for Shares
purchased pursuant to the Offer will in all cases be made by deposit of the Offer Price with CTT, which will act as agent for the tendering
Shareholders for the purpose of receiving payment from the Purchaser and transmitting payment to tendering Shareholders.
Under no circumstances will interest be paid
on the Offer Price by reason of any delay in making such payment. If any tendered Shares are not purchased for any reason (other than
due to proration as described above), the Assignment Form with respect to such Shares not purchased will be of no force or effect.
If, for any reason whatsoever, acceptance for payment of, or payment for, any Shares tendered pursuant to the Offer is delayed or the
Purchaser is unable to accept for payment, purchase or pay for Shares tendered pursuant to the Offer, then, without prejudice to the Purchaser’s
rights under Section 12 – Conditions of the Offer, CTT may instruct the Corporation’s transfer agent to retain
tendered Shares and such Shares may not be withdrawn (but subject to compliance with Rule 14e-1(c) under the Exchange Act, which
requires that the Purchaser pay the consideration offered or return the Shares deposited by or on behalf of the Shareholder promptly after
the termination or withdrawal of a tender offer), except to the extent that the tendering Shareholders are entitled to withdrawal rights
as described in Section 4 – Withdrawal Rights. If, prior to the Expiration Date, the Purchaser shall increase the consideration
offered to Shareholders pursuant to the Offer, such increased consideration shall be paid for all Shares accepted for payment pursuant
to the Offer, whether or not such Shares were tendered prior to such increase.
Section 3. Procedures for Tendering Shares.
Valid Tender. For Shares to be
validly tendered pursuant to the Offer, a properly completed and duly executed Assignment Form (a copy of which is included
with this Offer to Purchase and available at www.cttauctions.com/offerdisclosures) with any other documents required by the
Assignment Form must be received by CTT at its address set forth on the back cover of this Offer to Purchase on or prior to the
Expiration Date. A Shareholder may tender any or all Shares owned by such Shareholder. In order for a tendering Shareholder to
participate in the Offer, Shares must be validly tendered and not withdrawn prior to the Expiration Date, which is 11:59 p.m.,
Eastern Time, on September 6, 2023, or such date to which the Offer may be extended. The method of delivery of the Assignment
Form and all other required documents is at the option and risk of the tendering Shareholder and delivery will be deemed made
only when actually received by CTT.
Other Requirements. By executing an Assignment
Form as set forth above, a tendering Shareholder irrevocably appoints the designees of the Purchaser as such Shareholder’s
proxies, in the manner set forth in the Assignment Form, each with full power of substitution, to the full extent of such Shareholder’s
rights with respect to the Shares tendered by such Shareholder and accepted for payment by the Purchaser. Such appointment will be effective
when, and only to the extent that, the Purchaser accepts such Shares for payment. Upon such acceptance for payment, all prior proxies
given by such Shareholder with respect to such Shares will, without further action, be revoked, and no subsequent proxies may be given
(and if given will not be effective). The designees of the Purchaser will, with respect to such Shares, be empowered to exercise all voting
and other rights of such Shareholder as they in their sole discretion may deem proper at any meeting of Shareholders, by written consent
or otherwise. In addition, by executing an Assignment Form, a Shareholder also assigns to the Purchaser all of the Shareholder’s
rights to receive distributions from the Corporation with respect to Shares which are accepted for payment and purchased pursuant to the
Offer, other than those distributions paid during the period commencing on the Offer Date and terminating on the Expiration Date.
Determination of Validity; Rejection of Shares;
Waiver of Defects; No Obligation to Give Notice of Defects. All questions as to the validity, form, eligibility (including time of
receipt), and acceptance for payment of any tender of Shares pursuant to the procedures described above will be determined by the Purchaser,
in its sole discretion, which determination may be challenged in a court of competent jurisdiction. The Purchaser reserves the absolute
right to reject any or all tenders if not in proper form or if the acceptance of, or payment for, the Shares tendered may, in the opinion
of the Purchaser’s counsel, be unlawful. The Purchaser also reserves the right to waive any defect or irregularity in any tender
with respect to any particular Shares of any particular Shareholder, and the Purchaser’s interpretation of the terms and conditions
of the Offer (including the Assignment Form and the Instructions thereto) will be final and binding. Neither the Purchaser, CTT,
nor any other person will be under any duty to give notification of any defects or irregularities in the tender of any Shares or will
incur any liability for failure to give any such notification. A tender of Shares pursuant to any of the procedures described above will
constitute a binding agreement between the tendering Shareholder and the Purchaser upon the terms and subject to the conditions of the
Offer, including the tendering Shareholder’s representation and warranty that (i) such Shareholder owns the Shares being tendered
within the meaning of Rule 14e-4 under the Exchange Act (“Rule 14e-4”) and (ii) the tender of such Share complies
with Rule 14e-4. Rule 14e-4 requires, in general, that a tendering security holder actually be able to deliver the security
subject to the tender offer, and is of concern particularly to any Shareholders who have granted options to sell or purchase the Shares,
hold option rights to acquire such securities, maintain “short” positions in the Shares (i.e., have borrowed the Shares)
or have loaned the Shares to a short seller. A Shareholder will be deemed to tender Shares in compliance with Rule 14e-4 and the
Offer if the holder is the record owner of the Shares and the holder (i) delivers the Shares pursuant to the terms of the Offer,
(ii) causes such delivery to be made, (iii) guarantees such delivery, (iv) causes a guaranty of such delivery, or (v) uses
any other method permitted in the Offer (such as facsimile delivery of the Assignment Form).
Section 4. Withdrawal Rights. Shares
tendered pursuant to the Offer may be withdrawn at any time prior to the Expiration Date. In addition, tenders of Shares not accepted
for payment or not otherwise paid for by the Purchaser may be withdrawn at any time after September 8, 2023, the date that is sixty
(60) days from the date of this Offer to Purchase, including with respect to any tendered Shares for which the Purchaser has not completed
payment by such date. For withdrawal to be effective, a written or facsimile transmission notice of withdrawal must be timely received
by CTT at the address or the facsimile number set forth in the attached Assignment Form. Any such notice of withdrawal must specify the
name of the person who tendered the Shares to be withdrawn and must be signed by the person(s) who signed the Assignment Form in
the same manner as the Assignment Form was signed. If purchase of, or payment for, Shares is delayed for any reason or if the Purchaser
is unable to purchase or pay for Shares for any reason, then, without prejudice to the Purchaser’s rights under the Offer, tendered
Shares may be retained by CTT on behalf of the Purchaser and may not be withdrawn except to the extent that tendering Shareholders are
entitled to withdrawal rights as set forth in this Section 4 – Withdrawal Rights, subject to Rule 14e-1(c) under
the Exchange Act, which provides that no person who makes a tender offer shall fail to pay the consideration offered or return the securities
deposited by or on behalf of security holders promptly after the termination or withdrawal of the tender offer. All questions as to the
form and validity (including time of receipt) of notices of withdrawal will be determined by the Purchaser, in its sole discretion, which
determination may be challenged in a court of competent jurisdiction. Neither the Purchaser, nor CTT, nor any other person will be under
any duty to give notification of any defects or irregularities in any notice of withdrawal or will incur any liability for failure to
give any such notification. Any Shares properly withdrawn will be deemed not to be validly tendered for purposes of the Offer. Withdrawn
Shares may be re-tendered, however, by following the procedures described in Section 3 – Procedures for Tendering Shares
at any time prior to the Expiration Date.
Section 5. Extension of Tender
Period; Termination; Amendment. The Purchaser expressly reserves the right, in its sole discretion, at any time and from time to
time, (i) to extend the period of time during which the Offer is open and thereby delay acceptance for payment of, and the
payment for, any Shares by giving oral or written notice of such extension to CTT, (ii) upon the occurrence of any of the
conditions specified in Section 12 – Conditions of the Offer, to terminate the Offer and not accept for payment
any Shares by giving oral or written notice of such termination to CTT, and (iii) to amend the Offer in any respect (including,
without limitation, by increasing or decreasing the consideration offered or the number of Shares being sought in the Offer or both)
by giving oral or written notice of such amendment to CTT prior to the Expiration Date. Any extension, termination, or amendment
will be followed promptly by public announcement, the announcement in the case of an extension to be issued no later than 9:00 a.m.,
Eastern Time, on the next business day after the previously scheduled Expiration Date, in accordance with the public announcement
requirement of Rule 14d-4(d)(1) under the Exchange Act. Without limiting the manner in which the Purchaser may choose to
make any public announcement, except as provided by applicable law (including Rule 14d-4(d)(1) under the Exchange Act),
the Purchaser will have no obligation to publish, advertise, or otherwise communicate any such public announcement, other than by
issuing a press release. The Purchaser may also be required by applicable law to disseminate to Shareholders certain information
concerning the extensions of the Offer and any material changes in the terms of the Offer. The Purchaser will not provide a
subsequent offering period following the Expiration Date.
If the Purchaser extends the Offer, or if the
Purchaser (whether before or after its acceptance for payment of Shares) is delayed in its payment for Shares or is unable to pay for
Shares pursuant to the Offer for any reason, then, without prejudice to the Purchaser’s rights under the Offer, CTT may instruct
the Corporation’s transfer agent to retain tendered Shares on behalf of the Purchaser, and such Shares may be withdrawn to the extent
tendering Shareholders are entitled to withdrawal rights as described in Section 4 – Withdrawal Rights. However, the
ability of the Purchaser to delay payment for Shares that the Purchaser has accepted for payment is limited by Rule 14e-1 under the
Exchange Act, which requires that the Purchaser pay the consideration offered or return the securities deposited by or on behalf of holders
of securities promptly after the termination or withdrawal of the Offer, except that the Purchaser may delay payment until it receives
confirmation from the Corporation or its transfer agent that the Shares have been transferred to the Purchaser.
If the Purchaser makes a material change in the
terms of the Offer or the information concerning the Offer or waives a material condition of the Offer, the Purchaser will extend the
Offer to the extent required by Rules 14d-4(d)(1) and 14e-1 under the Exchange Act. The minimum period during which an offer
must remain open following a material change in the terms of the offer or information concerning the offer, other than a change in price
or a change in percentage of securities sought, will depend upon the facts and circumstances, including the relative materiality of the
change in the terms or information. With respect to a change in price or a change in percentage of securities sought (other than an increase
of not more than 2% of the securities sought), however, a minimum ten-business day period is generally required to allow for adequate
dissemination to security holders and for investor response. As used in this Offer to Purchase, “business day” means any day
other than a Saturday, Sunday or a federal holiday, and consists of the time period from 12:01 a.m. through midnight, Eastern Time.
Any material change in the terms of the Offer will be published, sent, or given to you in a manner reasonably designed to inform you of
such change; in most cases the Purchaser will mail you supplemental materials.
Section 6. Material U.S. Federal Income
Tax Consequences. THE U.S. FEDERAL INCOME TAX DISCUSSION SET FORTH BELOW DOES NOT PURPORT TO ADDRESS ALL ASPECTS OF TAXATION THAT MAY BE
RELEVANT TO A PARTICULAR SHAREHOLDER. For example, this discussion does not address the effect of any applicable non-U.S., state,
local or other tax laws other than U.S. federal income tax laws. Certain Shareholders (including trusts, non-U.S. persons, tax-exempt
organizations or corporations subject to special rules, such as life insurance companies or S corporations) may be subject to special
rules not discussed below. This discussion is based on the Internal Revenue Code of 1986, as amended (the “Code”), existing
regulations, court decisions and Internal Revenue Service rulings and other pronouncements. EACH SHAREHOLDER TENDERING SHARES SHOULD
CONSULT WITH SUCH SHAREHOLDER’S OWN TAX ADVISOR AS TO THE PARTICULAR TAX CONSEQUENCES TO SUCH SHAREHOLDER OF ACCEPTING THE OFFER, INCLUDING
THE APPLICATION OF THE ALTERNATIVE MINIMUM TAX AND U.S. FEDERAL, NON-U.S., STATE, LOCAL AND OTHER TAX LAWS.
Gain or Loss. A taxable Shareholder will
recognize a gain or loss on the sale of such Shareholder’s Shares in an amount equal to the difference between (i) the amount
realized by such Shareholder on the sale and (ii) such Shareholder’s tax basis in the Shares sold. If the Shareholder reports
a loss on the sale, such loss generally could not be currently deducted by such Shareholder except against such Shareholder’s capital
gains from other investments. The tax basis in the Shares of a Shareholder will depend upon individual circumstances. Each Shareholder
who plans to tender hereunder should consult with the Shareholder’s own tax advisor as to the Shareholder’s tax basis in the
Shareholder’s Shares and the resulting tax consequences of a sale. A tax-exempt Shareholder (other than an organization described
in Code Section 501(c)(7) (social club), 501(c)(9) (voluntary employee benefit association), 501(c)(17) (supplementary
unemployment benefit trust), or 501(c)(20) (qualified group legal services plan)) should not be required to recognize unrelated trade
or business income upon the sale of its Shares pursuant to the Offer, assuming that such Shareholder does not hold its Shares as a “dealer”
and has not acquired such Shares with debt financed proceeds.
Section 7. Effects of the Offer.
Limitations on Resales. The Purchaser does
not believe the provisions of the Corporation’s charter restrict transfers of Shares pursuant to the Offer.
Effect on Trading Market. If a substantial
number of Shares are purchased pursuant to the Offer the result would be a reduction in the number of Shareholders. Reducing the number
of security holders in certain kinds of equity securities might be expected to result in a reduction in the liquidity and volume of activity
in the trading market for the security. However, there is no established public trading market for the Shares and none is expected to
develop. Therefore, the Purchaser does not believe a reduction in the number of Shareholders will materially further restrict the Shareholders’
ability to find purchasers for their Shares through secondary market transactions.
Voting Power of Purchaser. The Corporation
holds annual meetings to elect directors and conduct other business. Votes of Shareholders might also be solicited for matters affecting
the fundamental structure of the Corporation. A Shareholder who tenders Shares to the Purchaser grants a proxy to the Purchaser as of
the date of acceptance of the tender, granting the Purchaser the right to vote such Shares in its sole discretion as to any matters for
which the Corporation has established a record date prior to the time such Shares are transferred by the Corporation to the Purchaser.
The Purchaser will have rights as a shareholder to vote on all matters subject to a shareholder vote. The Purchaser will be subject to
the ownership limitation of 9.8% set forth in the Corporation’s charter.
Section 8. Future Plans. Following
the completion of the Offer, the Purchaser, or its affiliates, may acquire additional Shares. Any such acquisitions may be made through
private purchases, one or more future tender offers or by any other means deemed advisable or appropriate. Any such acquisitions may be
at a consideration higher or lower than the consideration to be paid for the Shares purchased pursuant to the Offer. The Purchaser is
seeking to purchase a total of 8,800,000 Shares. If the Purchaser acquires fewer than 8,800,000 Shares pursuant to the Offer, the Purchaser
may seek to make further purchases on the open market at prevailing prices, or solicit Shares pursuant to one or more future tender offers
at the same price, a higher price or, if the Corporation’s circumstances change, at a lower price. Alternatively, the Purchaser
may discontinue any further purchases of Shares after termination of the Offer, regardless of the number of Shares purchased. The Offer
is not made with any current view toward or plan or purpose of acquiring Shares in a series of successive and periodic offers. Nevertheless,
as noted above, the Purchaser reserves the right to gauge the response to this solicitation, and, if not successful in purchasing 8,800,000
Shares in this Offer, may consider future offers. Factors affecting the Purchaser’s future interest in acquiring additional Shares
include, but are not limited to, the relative success of the current Offer, any increase or decrease in the availability of capital for
investment by the Purchaser and its investment fund affiliates, the current diversification and performance of each affiliated fund’s
portfolio of real estate interests, the development of any public market in the Shares or actions by unrelated parties to tender for or
purchase Shares, the status of and changes and trends in the Corporation’s operations, announcement of pending property sales and
the proposed terms of sales, and local and national real estate and financial market developments and trends.
The Purchaser is acquiring the Shares pursuant
to the Offer solely for investment purposes. The Purchaser has no present intention to seek control of the Corporation or to change the
management or operations of the Corporation. The Purchaser does not have any present intention to take any action in connection with the
liquidation of the Corporation. The Purchaser will have rights as a shareholder to vote on all matters subject to a shareholder vote.
The Purchaser will be subject to the ownership limitation of 9.8% set forth in the Corporation’s charter.
Section 9. The Business of the Corporation.
For information about the Corporation, please refer to the 2022 Form 10-K, the Corporation’s Quarterly Reports on Form 10-Q
and any other materials filed by the Corporation with the Commission or sent to you by the Corporation. These documents contain updated
information concerning the Corporation, including detailed information regarding the properties owned, including mortgages, rental rates,
operations, management, and taxes. In addition, the Corporation is subject to the information and reporting requirements of the Exchange
Act and information about the Corporation can be obtained on the Commission’s EDGAR system, at its internet web site at www.sec.gov.
Section 10. Certain Information Concerning
the Purchaser. The Purchaser is Comrit Investments 1, Limited Partnership, a Cayman Islands Exempted Limited Partnership. For information
concerning the Purchaser and its principals, please refer to Schedule I attached hereto. The principal business of the Purchaser is investment
in securities, particularly real estate-based securities. The principal business address of the Purchaser is 9 A’had Ha’am
St., Tel Aviv, P.O.B 29161, 61291, Israel. The Purchaser has made a binding commitment to contribute and has available sufficient
amounts of capital necessary to fund the acquisition of all Shares subject to the Offer, the expenses to be incurred in connection with
the Offer, and all other anticipated costs of the Purchaser. The Purchaser is not a public company. The Purchaser has invested approximately
$300 million in non-traded real estate investment trusts in the United States. The Purchaser has aggregate assets that are more than sufficient
to fund its obligation to purchase Shares in this Offer and any other outstanding tender offers.
Except as otherwise set forth herein,
(i) neither the Purchaser nor, to the best knowledge of the Purchaser, the persons listed on Schedule I nor any affiliate of
the Purchaser beneficially owns or has a right to acquire any Shares, (ii) neither the Purchaser nor, to the best knowledge of
the Purchaser, the persons listed on Schedule I nor any affiliate of the Purchaser, or any director, executive officer or subsidiary
of any of the foregoing has effected any transaction in the Shares within the past 60 days, (iii) neither the Purchaser nor, to
the best knowledge of the Purchaser, the persons listed on Schedule I nor any affiliate of the Purchaser has any contract,
arrangement, understanding or relationship with any other person with respect to any securities of the Corporation, including but
not limited to, contracts, arrangements, understandings or relationships concerning the transfer or voting thereof, joint ventures,
loan or option arrangements, puts or calls, guarantees of loans, guarantees against loss or the giving or withholding of proxies,
consents or authorizations, (iv) there have been no transactions or business relationships which would be required to be
disclosed under the rules and regulations of the Commission between the Purchaser or, to the best knowledge of the Purchaser,
the persons listed on Schedule I, or any affiliate of the Purchaser on the one hand, and the Corporation or its affiliates, on the
other hand, (v) there have been no contracts, negotiations or transactions between the Purchaser, or to the best knowledge of
the Purchaser any affiliate of the Purchaser (including the persons listed on Schedule I), on the one hand, and the Corporation or
its affiliates, on the other hand, concerning a merger, consolidation or acquisition, tender offer or other acquisition of
securities, an election of directors or a sale or other transfer of a material amount of assets, (vi) no person listed on
Schedule I has been convicted in a criminal proceeding during the past five years (excluding traffic violations or similar
misdemeanors), and (vii) no person listed on Schedule I has been a party to any judicial or administrative proceeding during
the past five years (except for matters dismissed without sanction or settlement) that resulted in a judgment, decree, or final
order enjoining the person from future violations of, or prohibiting activities subject to, federal or state securities laws, or a
finding of any violation of federal or state securities laws.
Section 11. Source of Funds. The Purchaser
expects that approximately $36,168,000 would be required to purchase 8,800,000 Shares, if tendered, and up to an additional $500,000 may
be required to pay related fees and expenses. The Purchaser anticipates funding all of the purchase price and related expenses through
its available cash on hand. The cash and liquid securities necessary to complete the entire purchase are readily available and are committed
to that purpose. Accordingly, there are no financing arrangements to fall through and no alternative financing plans.
Section 12. Conditions of the Offer.
Notwithstanding any other term of the Offer, the Purchaser shall not be required to accept for payment or to pay for any Shares tendered
unless all authorizations or approvals of, or expirations of waiting periods imposed by, any court, administrative agency or other governmental
authority necessary for the consummation of the transactions contemplated by the Offer shall have been obtained or occurred on or before
the Expiration Date. As of the Offer Date, the Purchaser is unaware of any such required authorizations, approvals, or waiting periods
relating to this Offer. The Purchaser shall not be required to accept for payment or pay for any Shares and may terminate or amend the
Offer as to such Shares if, at any time on or after the date of the Offer and before the Expiration Date, any of the following conditions
exists:
(a) a preliminary or
permanent injunction or other order of any federal or state court, government or governmental authority or agency shall have been issued
and shall remain in effect which (i) makes illegal, delays or otherwise directly or indirectly restrains or prohibits the making
of the Offer or the acceptance for payment of or payment for any Shares by the Purchaser, (ii) imposes or confirms limitations on
the ability of the Purchaser effectively to exercise full rights of ownership of any Shares, including, without limitation, the right
to vote any Shares acquired by the Purchaser pursuant to the Offer or otherwise on all matters properly presented to the Corporation’s
Shareholders, (iii) requires divestiture by the Purchaser of any Shares, (iv) causes any material diminution of the benefits
to be derived by the Purchaser as a result of the transactions contemplated by the Offer (see the discussion of such benefits in the Summary
Term Sheet and Introduction sections of this Offer to Purchase) or (v) materially adversely affect the business, properties, assets,
liabilities, financial condition, operations, results of operations or prospects of the Corporation, in the reasonable judgment of the
Purchaser;
(b) there shall be: (i) any
statute, rule, regulation, or order proposed, enacted, enforced, promulgated, issued, or deemed applicable to the Offer by any federal
or state court, government, or governmental authority or agency, other than the application of the waiting period provisions of the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended; or (ii) any other action taken; either of which will, directly or indirectly, result
in any of the consequences referred to in clauses (i) through (v) of paragraph (a) above;
(c) any change or development
shall have occurred or been threatened since the date hereof, in the business, properties, assets, liabilities, financial condition, operations,
results of operations or prospects of the Corporation, which, in the reasonable judgment of the Purchaser, is or will be materially adverse
to the Corporation, or the Purchaser shall have become aware of any fact that, in the reasonable judgment of the Purchaser, does or will
have a material adverse effect on the value of the Shares;
(d) there shall
have occurred (i) any general suspension of trading in securities on any national securities exchange or in the
over-the-counter market in the United States, (ii) a declaration of a banking moratorium or any suspension of payments in
respect of banks in the United States, (iii) any limitation by any governmental authority on, or other event which might
affect, the extension of credit by lending institutions or result in any imposition of currency controls in the United States,
(iv) a commencement of a war or armed hostilities or other national or international calamity directly or indirectly involving
the United States (which, for the avoidance of doubt, excludes the current state of the ongoing COVID-19 pandemic), (v) a
material change in United States currency exchange rates or a suspension or a limitation on the markets thereof, or (vi) in the
case of any of the foregoing existing at the time of the commencement of the Offer, a material acceleration or worsening thereof
(other than a material acceleration or worsening of the current state of the COVID-19 pandemic without the existence of accompanying
factors, conditions or events that would give rise to another of the conditions described in this Section 12); or
(e) it shall have been
publicly disclosed or the Purchaser shall have otherwise learned that (i) more than fifty percent (50%) of the outstanding Shares
have been or are proposed to be acquired by another person (including a “group” within the meaning of Section 13(d)(3) of
the Exchange Act), or (ii) any person or group that prior to such date had filed a Statement with the Commission pursuant to Sections
13(d) or (g) of the Exchange Act has increased or proposes to increase the number of Shares beneficially owned by such person
or group as disclosed in such Statement by two percent (2%) or more of the outstanding Shares.
The foregoing conditions are for the sole benefit of the Purchaser
and may be asserted by the Purchaser or may be waived by the Purchaser in whole or in part upon the Purchaser’s becoming aware of
any of the foregoing conditions in its sole exercise of reasonable discretion, and the Offer will remain open for a period of at least
five business days following any such waiver of a material condition. However, if the Purchaser waives a certain condition for one tendering
Shareholder, the Purchaser will waive that condition for all Shareholders tendering Shares. Any determination by the Purchaser concerning
the events described above will be final and binding upon all parties, subject, of course, to the parties’ ability to seek review
of any contested determination by an arbitrator pursuant to Section 15 – Miscellaneous.
Section 13. Certain Legal Matters.
General. Except as set forth in this Section 13
– Certain Legal Matters, the Purchaser is not aware of any filings, approvals or other actions by any domestic or foreign
governmental or administrative agency that would be required prior to the acquisition of Shares by the Purchaser pursuant to the Offer.
Should any such approval or other action be required, it is the Purchaser’s present intention that such additional approval or action
would be sought. While there is no present intent to delay the purchase of Shares tendered pursuant to the Offer pending receipt of any
such additional approval or the taking of any such action, there can be no assurance that any such additional approval or action, if needed,
would be obtained without substantial conditions or that adverse consequences might not result to the Corporation’s business, or
that certain parts of the Corporation’s business might not have to be disposed of or held separate or other substantial conditions
complied with in order to obtain such approval or action, any of which could cause the Purchaser to elect to terminate the Offer without
purchasing Shares thereunder. The Purchaser’s obligation to purchase and pay for Shares is subject to certain conditions set forth
in Section 12 – Conditions of the Offer, the satisfaction of which may be contingent on, among other things, the legal
matters discussed in this Section 13 – Certain Legal Matters.
Antitrust. The Purchaser does not believe
that the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, is applicable to the acquisition of Shares pursuant to the
Offer.
Margin Requirements. The Shares are not
“margin securities” under the regulations of the Board of Governors of the Federal Reserve System and, accordingly, such regulations
are not applicable to the Offer.
State Takeover Laws. A number of states
have adopted anti-takeover laws which purport, to varying degrees, to be applicable to attempts to acquire securities of corporations
which are incorporated in such states or which have substantial assets, security holders, principal executive offices or principal places
of business therein. The Purchaser is not seeking a controlling block of Shares or such a number of Shares as to fall within these state
statutes and, therefore, does not believe that any anti-takeover laws apply to the transactions contemplated by the Offer. Although the
Purchaser has not attempted to comply with any state anti-takeover statutes in connection with the Offer, the Purchaser reserves the right
to challenge the validity or applicability of any state law allegedly applicable to the Offer and nothing in this Offer or any action
taken in connection herewith is intended as a waiver of such right. If any state anti-takeover statute is applicable to the Offer, the
Purchaser might be unable to accept for payment or purchase Shares tendered pursuant to the Offer or be delayed in continuing or consummating
the Offer. In such case, the Purchaser may not be obligated to accept for purchase or pay for any Shares tendered.
Section 14. Fees and Expenses.
The Purchaser has retained CTT to facilitate the settlement of and payment for the tendered Shares in conjunction with
Corporation’s transfer agent. As compensation for such services, the Purchaser will pay CTT a fee in the amount of 2% of the
aggregate purchase price, plus reimbursement for out-of-pocket expenses, as well as a $5,000 administrative fee. This payment should
not be deemed to imply an endorsement by CTT of the Offer. In addition, in the event a Shareholder has a relationship with an
independent representative of CTT, that relationship is separate and apart from the Offer and any action on the part of a
Shareholder is his or her own decision. CTT is not promoting or endorsing the Offer in any way and owes no duty to the Shareholders,
fiduciary or otherwise, to advise them of their rights under the Offer. The Purchaser will also pay all costs and expenses of
printing, publication and mailing of the Offer and all costs of transfer.
Additionally, the Purchaser will pay Independent
Financial Group, LLC (“IFG”), member FINRA and SIPC, 5% of the aggregate purchase price in connection with the Offer. As a
registered broker-dealer, IFG offers a platform that provides brokerage services to retail investors. Shares received in connection
with the Offer are deposited into an account maintained by the Purchaser with IFG. Through its clearing agent and/or other third-party
vendors, IFG provides the Purchaser with services regarding that account, including electronic access to information, monthly/quarterly
statements and transaction confirmations. Of the amount payable to IFG, IFG will pay Ittai Dvir, in his capacity as registered representative
of IFG, 4.5% of the aggregate purchase price for services related to the Offer. The services provided to the Purchaser by Mr. Dvir
include coordination of printing and mailing of the Offer documents, reconciliation of completed Assignment Forms, and administration
and publication of Purchaser announcements related to the Offer. The payments described in this Section 14 should not be deemed to
imply an endorsement by IFG or Ittai Dvir of the Offer. In addition, in the event a Shareholder has a relationship with either of Ittai
Dvir or an independent representative of IFG, that relationship is separate and apart from the Offer and any action or decision on the
part of a Shareholder as to whether or not to tender Shares in connection with the Offer. IFG and Ittai Dvir are not promoting or endorsing
the Offer in any way and do not owe any duty to the Shareholders, fiduciary or otherwise, to advise them of their rights under the Offer.
Section 15. Miscellaneous. THE OFFER
IS NOT BEING MADE TO (NOR WILL TENDERS BE ACCEPTED FROM OR ON BEHALF OF) SHAREHOLDERS IN ANY U.S. STATE IN WHICH THE MAKING OF THE OFFER
OR THE ACCEPTANCE THEREOF WOULD NOT BE IN COMPLIANCE WITH THE LAWS OF SUCH U.S. STATE. THE PURCHASER IS NOT AWARE OF ANY JURISDICTION
WITHIN THE UNITED STATES IN WHICH THE MAKING OF THE OFFER OR THE ACCEPTANCE THEREOF WOULD BE ILLEGAL.
No person has been authorized to give any information
or to make any representation on behalf of the Purchaser not contained herein or in the Assignment Form and, if given or made, such
information or representation must not be relied upon as having been authorized.
Further, by tendering your Shares in the Offer,
you are agreeing to arbitrate any disputes related to the Offer that may arise between you and the Purchaser or its affiliates, to subject
yourself to personal jurisdiction in Maryland, and that the prevailing party in any such action will be entitled to recover attorney fees
and costs. However, by so doing, you are not waiving any party’s compliance with, or any of your rights under, the federal securities
laws or any rule or regulation promulgated thereunder. As further set forth in the Assignment Form, any dispute or claim arising
out of or related to the Offer shall be resolved by binding arbitration in Denver, Colorado before a retired judge. The arbitration shall
be administered by JAMS pursuant to its Arbitration Rules and Procedures (“JAMS Rules”). In any arbitration arising out
of the arbitration agreement contained in the Assignment Form, the prevailing party or parties (who may include tendering Shareholders
who have successfully established loss causation) shall be entitled to recover all of their costs and expenses, including reasonable attorneys’
fees, arbitrator fees, expert witness fees and costs, JAMS fees and costs, and any fees and costs incurred in compelling arbitration.
In making an award of attorneys’ fees, the arbitrator is not required to take into account any minimum level of expenditure on such
fees or any minimum amount of Shares tendered by the plaintiff, if a Shareholder. Your agreement to arbitrate any such dispute or claim
is subject to risks, including, but not limited to: the potential for increased costs of bringing a claim using arbitration under the
JAMS Rules, which may exceed the costs of litigating in a court of competent jurisdiction; that the Purchaser may have greater financial
resources than you to cover the costs of arbitration prior to the determination of the arbitrator’s final decision or award; limited
access to information and lack of familiarity with the JAMS Rules when compared to the Purchaser; and the risk that you will be discouraged,
limited or precluded from litigating your claim or dispute in a judicial forum you find favorable. Further, although federal law favors
enforcement of valid arbitration agreements, such agreements may be revoked or held to be unenforceable on the same grounds as those of
other contracts, including unconscionability. Therefore, your agreement to arbitrate may be challenged in a court of competent jurisdiction
and it is uncertain whether such a court would enforce the arbitration agreement in all circumstances. As further described in the Assignment
Form, and subject to the possibility that a court may revoke or refuse to enforce an arbitrator’s decision or award, the arbitrator’s
decision will be final and binding on all parties, and a judgment on any award may be entered in a court of competent jurisdiction. Additionally,
while the arbitrator’s award shall not preclude any party from seeking provisional remedies in aid of arbitration from a court of
competent jurisdiction, the arbitrator’s award may have the effect of limiting or precluding future claims related to the Offer,
especially if such future claims relate to the same issue or issues of law and/or are deemed to have been finally and conclusively determined
by the arbitrator.
SCHEDULE I
THE PURCHASER AND ITS PRINCIPALS
The Purchaser is Comrit Investments
1, Limited Partnership, a Cayman Islands Exempted Limited Partnership. Comrit Investments Ltd., a limited liability private company organized
under the laws of the State of Israel, is the general partner of the Purchaser (the “General Partner”). The names of the controlling
persons and executive officers of the General Partner are set forth below.
The Investment Committee
The Purchaser has an Investment
Committee composed of three members, which are currently Iddo Kook, David Lubetzky, and Ziv Sapir (Mr. Sapir is referred to herein
as the “Principal”). The number of members in the Investment Committee and/or their identities may be amended from time to
time by the General Partner in its sole discretion. The Investment Committee sets investment guidelines for the General Partner and the
Principal to invest on behalf of the Purchaser within which, subject to the Purchaser’s investment objectives, the General Partner
and the Principal shall have the right in their joint sole discretion to decide on behalf of the Purchaser whether and to what extent
the Purchaser will participate in a particular investment.
Comrit Investments Ltd.
General
The General Partner was incorporated
under the laws of the State of Israel on January 12, 2015 and registered as a foreign company in the Cayman Islands on January 29,
2015. Its principal office is located at 9 A’had Ha’am St., Tel Aviv, P.O.B 29161, 61291, Israel. The General Partner
manages the day-to-day business and affairs of the Purchaser, subject to oversight by the Investment Committee. The General Partner has
the authority to, and may, engage one or more firms to serve as custodian, broker-dealers, investment adviser and/or administrator for
the Purchaser.
Management of the General Partner
The General Partner is not
registered as an investment adviser under the Investment Advisers Act and is not registered as an investment portfolio manager under the
Israeli Regulation of Investment Advice, Investment Marketing and Investment Portfolio Management Law, 1995. The equity in the General
Partner is owned 70% by I.B.I. Investment House Ltd (“I.B.I.”) and 30% by O&E Sapir Investments Ltd.
I.B.I.
I.B.I., an Israeli public
company traded on the Tel Aviv Stock Exchange, has over 40 years of experience in the Israeli capital markets. I.B.I. manages over NIS
50 billion in a wide range of financial services, including, but not limited to: mutual funds, provident funds, study funds and investment
portfolios management, institutional brokerage services both for local and offshore markers, internet trading for private clients etc.
I.B.I. also manages assets on behalf of institutional investors, corporations, non-profit organizations, research funds and private clients.
Backed by its research department, I.B.I. also owns one of the largest underwriting companies in Israel.
Iddo Kook
Mr. Kook is an experienced
investment manager in the Israeli capital markets with more than 20 years of experience. Mr. Kook is a licensed portfolio manager
and has served as the Chairman of the Board of I.B.I. since 2019. From 2011 to 2019, Mr. Kook served as the CEO of I.B.I. Mr. Kook
also serves as a board director on several additional companies affiliated with IBI Group, each of which is located at 9 Migdal Shalom
Fl. 27, Tel Aviv, Israel. Mr. Kook received a B.Sc in life science and an MBA from Tel Aviv University. Mr. Kook is a citizen
of Israel.
David Lubetzky
Mr. Lubetzky is the current
CEO of I.B.I. and Chairman of IBI Portfolio Management, positions he has held since 2019. From 2012 to 2019, Mr. Lubetzky served
as CEO of I.B.I. Amban Asset Management. Mr. Lubetzky also serves as board director on several additional companies affiliated with
IBI Group, each of which is located at 9 Migdal Shalom Fl. 27, Tel Aviv, Israel. Mr. Lubetzky received a B.A. in economics from
Tel Aviv University and is a licensed portfolio manager. Mr. Lubetsky is a citizen of Israel.
Ziv Sapir
Mr. Sapir has more than
16 years of experience in capital markets. Before joining I.B.I. Investment House Ltd. in 2014, Mr. Sapir served as VP investment
in Migdal Capital Markets Ltd., an Israeli investment house owned by one of the largest insurance companies in Israel, Migdal, establishing
and operating the company's offshore investment desk. Mr. Sapir currently serves as the CEO of the General Partner, a position he
has held since 2015, and Mr. Sapir is also in charge of I.B.I.’s offshore investments and alternative investment funds. Mr. Sapir
received a B.A. in Finance from the Interdisciplinary Center and an M.A. in Law from Bar Ilan University and is a licensed portfolio manager.
Mr. Sapir is a citizen of Israel.
None of Messrs. Kook,
Lubetsky or Sapir have been convicted in a criminal proceeding during the past five years (excluding traffic violations or similar misdemeanors).
None of Messrs. Kook, Lubetsky or Sapir has been a party to any judicial or administrative proceeding during the past five
years (except for matters that were dismissed without sanction or settlement) that resulted in a judgment, decree or final order enjoining
him from future violations of, or prohibiting activities subject to, federal or state securities laws, or a finding of any violation of
federal or state securities laws.
Exhibit (a)(2)
Assignment Form
Please complete this form and send it back to us in the pre-addressed
envelope.
YOU NEED TO OBTAIN a Medallion Signature Guarantee at your
local bank or broker.
If you have any questions, please call us at 1-800-327-9990.
Please return to:
365 S. Garden Grove Lane, Suite 100
Pleasant Grove, Utah 84062
Attn: Comrit Investments 1, Limited Partnership
| 1. | Complete or Correct Name and Address Information if Necessary |
| | CNL Healthcare Properties, Inc. Purchase Offer |
|
Quantity Owned: |
| | |
|
|
| | Name: |
|
|
Common Shares: |
|
| | |
|
|
| | Address: |
|
|
Price: $4.11/Share |
| | |
|
Offer Expires: September 6, 2023 |
| | City, State, ZIP: |
|
|
|
| 2. | List the number of Shares you are selling: |
| | |
| |
¨ All
¨Quantity: |
| 3. | Fill out where applicable, signing to indicate your agreement to the terms of the Offer and the terms on this side and reverse
side of this form (collectively, the “Agreement”). |
| Owner & Custodian Information |
|
Medallion Signature Guarantee |
|
|
Owner*
Name: _____________________________________________
Signature: __________________________________________
Social Security #:______________ Phone #:______________
Email Address:______________________________________ |
Date __________ |
(Please obtain a Medallion Guarantee Stamp here from your
bank or broker) |
|
|
Co-Owner(s) (if applicable)
Name(s): ___________________________________________
Signature(s): ________________________________________ |
Date __________ |
|
|
(Place co-owner's Medallion Guarantee Stamp here, or the
Purchaser will obtain the custodian's stamp here if this is an IRA or other custodial account) |
|
|
Custodian (if applicable; the Purchaser will obtain)
Name: _____________________________________________
Signature: __________________________________________
IRA or Tax #: ________________ Phone #:_______________ |
Date __________ |
|
| *If signature is by trustee(s), executor(s), administrator(s), guardian(s),
attorney(s) in fact, agent(s), officer(s), or a corporation or another acting in a fiduciary or representing capacity, please provide
the following information: |
|
Signature: |
|
Capacity: |
|
| 4. | If any of the following applies, please provide the
appropriate documents |
| · | Name changes: Certified copy of Marriage Certificate or proof of name
change from the court. |
| · | Power of Attorney: Copy of Power of Attorney document. |
| · | Estates: Certified Copies of Death Certificate and appropriate Court
Documents (no older than 45 days). |
| · | Corporation: Copy of Corporate Resolution naming the Authorized Signature,
with a seal if applicable. |
THE OFFER AND PRORATION PERIOD WILL EXPIRE AT 11:59 P.M., EASTERN
TIME, ON SEPTEMBER 6, 2023 (THE “EXPIRATION DATE”) UNLESS EXTENDED.
CNL Healthcare Properties, Inc. Assignment
Form
To participate in the Offer, a duly executed copy
of this Assignment Form and any other documents required by this Assignment Form must be received by the Purchaser on or prior
to the Expiration Date. If your Shares are held in a custodial or brokerage account, you must mail your completed Assignment Form and
any other required documents to your broker or financial advisor instead of the Purchaser. Delivery of this Assignment Form or any
other required documents to an address other than as set forth above, or to your broker or financial advisor, as applicable, does not
constitute valid delivery. The method of delivery of all documents is at the election and risk of the tendering Shareholder. This Assignment
Form is to be completed by holders of Shares in CNL Healthcare Properties, Inc. (the “Corporation”), pursuant to
the procedures set forth in the Offer to Purchase (as defined below). Capitalized terms used herein have the meanings set forth in the
Offer to Purchase.
The undersigned hereby tenders to Comrit
Investments 1, Limited Partnership (the “Purchaser”), the number of shares of common stock, par value $0.01 per share
(“Shares”), in the Corporation held by the undersigned as set forth above (or, if less than all such Shares, the number
set forth on the reverse above the signature box), at a purchase price equal to $4.11 per Share, upon the other terms and subject to
the conditions set forth in the Offer to Purchase, dated July 10, 2023 (the “Offer to Purchase”), and in this
Assignment Form, as each may be supplemented or amended from time to time (which together constitute the “Offer”).
Receipt of the Offer to Purchase is hereby acknowledged. Subject to and effective upon acceptance for payment of any of the Shares
tendered hereby, the undersigned sells, assigns, and transfers to, Purchaser all right, title, and interest in and to such Shares
which are purchased pursuant to the Offer. The undersigned hereby irrevocably constitutes and appoints the Purchaser as the true and
lawful agent and attorney-in-fact and proxy of the undersigned with respect to such Shares, with full power of substitution (such
power of attorney and proxy being deemed to be an irrevocable power and proxy coupled with an interest), to deliver such Shares and
transfer ownership of such Shares, on the books of the Corporation, together with all accompanying evidences of transfer and
authenticity, to the Purchaser and, upon acceptance of the tender of such Shares by the Purchaser, to exercise all voting rights and
to receive all benefits and otherwise exercise all rights of beneficial ownership of such Shares all in accordance with the terms of
the Offer. Upon the purchase of Shares pursuant to the Offer, all prior proxies and consents given by the undersigned with respect
to such Shares will be revoked and no subsequent proxies or consents may be given (and if given will not be deemed effective). In
addition, by executing this Assignment Form, the undersigned assigns to the Purchaser all of the undersigned’s rights to
receive distributions from the Corporation with respect to Shares which are purchased pursuant to the Offer, other than
distributions paid through the Expiration Date, and all proceeds that are paid after the Expiration Date from or as a result of any
claim, litigation, class or derivative action brought by or for the benefit of the shareholders with respect to the transferred
Shares, regardless of when the claims brought pursuant to such action accrued. Upon request, the Seller will execute and deliver,
and irrevocably directs any custodian to execute and deliver, any additional documents deemed by the Purchaser to be necessary or
desirable to complete the assignment, transfer, and purchase of such Shares, including obtaining a Medallion Signature Guarantee if
necessary (which may be required for transfer; the lack thereof does not affect the validity of the Agreement). The Purchaser is not
affiliated with the Corporation and is seeking to profit from the Offer. The Corporation established an estimated net asset value
per Share (“Estimated Per Share NAV”) of $6.92 as of December 31, 2022. The Corporation may publish an update to
its Estimated Per Share NAV during the period in which the Offer is open. Shareholders should consult the Corporation’s public
filings pursuant to the Securities Exchange Act of 1934, as amended, for any such updates, which are available at www.sec.gov.
The undersigned hereby represents and warrants
that the undersigned owns the Shares tendered hereby and has full power and authority to validly tender, sell, assign, and transfer the
Shares tendered hereby, and that when any such Shares are purchased by the Purchaser, the Purchaser will acquire good, marketable, and
unencumbered title thereto, free and clear of all liens, restrictions, charges, encumbrances, conditional sales agreements, or other obligations
relating to the sale or transfer thereof, and such Shares will not be subject to any adverse claim. Upon request, the undersigned will
execute and deliver any additional documents deemed by the Purchaser to be necessary or desirable to complete the assignment, transfer,
and purchase of Shares tendered hereby. The undersigned understands that a tender of Shares to the Purchaser will constitute a binding
agreement between the undersigned and the Purchaser upon the terms and subject to the conditions of the Offer. The undersigned recognizes
the right of the Purchaser to effect a change of distribution address to 365 S. Garden Grove Lane, Suite 100, Pleasant Grove, Utah
84062, Attn: Comrit Investments 1, Limited Partnership. The undersigned recognizes that under certain circumstances set forth in the Offer
to Purchase, the Purchaser may not be required to accept for payment any of the Shares tendered hereby. In such event, the undersigned
understands that any Assignment Form for Shares not accepted by Purchaser will be destroyed by the Purchaser. All authority herein
conferred or agreed to be conferred shall survive the death or incapacity of the undersigned and any obligations of the undersigned shall
be binding upon the heirs, personal representatives, successors and assigns of the undersigned. Except as stated in the Offer to Purchase,
this tender is irrevocable.
Arbitration Agreement: Purchaser and Seller
agree that any dispute or claim arising out of or related to the Agreement or a purchase of Shares shall be resolved by binding arbitration
in Denver, Colorado before a retired judge. The arbitration shall be administered by JAMS pursuant to its Arbitration Rules and Procedures
(“Rules”). If one party fails to respond within twenty days after the other party mails a written list of arbitrators by either
agreeing to one of the proposed arbitrators or suggesting three or more alternate arbitrators, the proposing party may select the arbitrator
from among its initial list and JAMS shall then appoint that arbitrator to preside over the arbitration. If the parties are unable to
agree on an arbitrator, the parties shall select an arbitrator pursuant to the Rules. Where reasonable, the arbitrator shall schedule
the arbitration hearing within four months after being appointed. The arbitrator must render a decision in writing, explaining the legal
and factual basis for decision as to each of the principal controverted issues. The arbitrator's decision will be final and binding upon
the parties. A judgment upon any award may be entered in a court of competent jurisdiction. Each party shall be responsible for advancing
one-half of the costs of arbitration, including all JAMS fees. The parties are not waiving, and expressly reserve, any rights they may
have under federal securities laws, rules, and regulations. The Agreement will be interpreted, construed, and governed according to federal
securities laws and the laws of the State of Colorado; provided that all matters relating to arbitration shall be governed by the Federal
Arbitration Act (9 U.S.C. Sections 1 et seq.). If both parties waive their right to arbitrate, then any dispute or claim arising out of
or related to the Agreement will be subject to the exclusive jurisdiction of the federal courts sitting in the County and City of Denver,
Colorado. In any such action, Purchaser and Seller expressly submit and consent to the exclusive jurisdiction of the federal courts sitting
in the County and City of Denver, Colorado and waive all defenses to jurisdiction and venue. In any arbitration or court action arising
out of the Agreement or a purchase of Shares, the prevailing party shall be entitled to recover all of its costs and expenses, including
reasonable attorneys’ fees, arbitrator fees, expert witness fees and costs, JAMS fees and costs, and any fees and costs incurred
in compelling arbitration.
Exhibit (a)(3)
July 10, 2023
RE: Liquidation Opportunity for CNL Healthcare Properties, Inc.
Dear Shareholder,
Congratulations! Now you can sell your shares of common stock of CNL
Healthcare Properties, Inc. (the “REIT”) for $4.11 per share in cash. Comrit Investments 1, Limited
Partnership (the “Purchaser”) is offering to pay you cash by purchasing up to 8,800,000 shares of the REIT’s
common stock. But this offer expires on September 6, 2023, so you must act soon.
Based on the REIT’s public filings, including the statements
below, we believe that shareholders’ liquidity is extremely limited. Specifically, the REIT’s filings say:
| · | There is no established public trading market for the REIT’s common
stock. Therefore, there is a risk that a stockholder may not be able to sell shares at a time or price acceptable to the stockholder,
or at all. Unless and until the REIT’s shares are listed on a national securities exchange, it is not expected that a public market
for the shares will develop. |
| · | Effective July 11, 2018, the REIT suspended its stock redemption
plan. |
| · | The REIT estimated its per share NAV at $6.92 as of December 31,
2022. Shareholders should consult the REIT’s public filings pursuant to the Securities Exchange Act of 1934, as amended, for any
such updates, which are available at www.sec.gov. |
This offer will:
| · | Allow you to take advantage of this opportunity to receive cash for your
investment. |
| · | Eliminate the uncertainty of holding shares that currently have no liquid
trading market. |
| · | Provide you with more control over your investments and your money today. |
The Purchaser is not affiliated with the REIT or its management. The
Purchaser and its affiliates currently own 2,493,680 shares of the REIT’s common stock, or approximately 1.4% of the common stock
outstanding as of May 10, 2023.
If you are interested in this opportunity, please carefully review
the included Offer to Purchase and complete the enclosed Assignment Form in order to secure your price and get cash for your shares.
The full Offer to Purchase and other related documents are also available for review at www.cttauctions.com/offerdisclosures.
If you act today, you can take part in this opportunity. The Purchaser
will mail your check within three business days after the REIT confirms the transfer of shares, subject to any extensions of such time
period that may be necessary due to the settlement practices of non-traded real estate investment trusts, some of which are outside the
Purchaser’s control.
If you choose to sell your shares to the Purchaser, please complete
the enclosed Assignment Form and return it as soon as possible.
If you have any questions, please contact Central Trade and Transfer,
LLC at 1-800-327-9990.
Warm regards,
Comrit Investments 1, LP
By: Comrit Investments Ltd., its General Partner
| By: |
/s/ Ziv Sapir |
|
| Ziv Sapir, Chief Executive Officer |
Exhibit (a)(4)
This announcement is neither an offer to buy
nor a solicitation of an offer to sell securities. Such offer is being made solely by the Offer to Purchase provided to shareholders
of record and is not being made to, and tenders will not be accepted from or on behalf of, shareholders residing in any state in which
making or accepting the offer would violate that jurisdiction’s laws. In those jurisdictions where the securities, Blue Sky, or
other laws require the offer to be made by a licensed broker or dealer, the offer shall be deemed to be made on behalf of the Purchaser
only by one or more registered dealers licensed under the laws of such jurisdiction.
NOTICE OF OFFER TO PURCHASE
FOR CASH:
Up to 8,800,000 Shares
of common stock of
CNL HEALTHCARE PROPERTIES, INC.
(the “REIT”)
at a price of $4.11 per Share
by: Comrit Investments 1, Limited Partnership (the “Purchaser”)
The Purchaser is offering to purchase for
cash up to 8,800,000 shares of common stock (“Shares”) of the REIT at a price of $4.11 per Share upon the terms and subject
to the conditions set forth in the Purchaser’s Offer to Purchase and in the related Assignment Form for the offer (which together
constitute the “Offer” and the “Tender Offer Documents”). THE OFFER AND RELATED WITHDRAWAL RIGHTS EXPIRE
AT 11:59 P.M., EASTERN TIME, ON SEPTEMBER 6, 2023, UNLESS THE OFFER IS EXTENDED.
The Purchaser is not affiliated with the REIT and is seeking to profit
from the Offer. The REIT established an estimated net asset value per Share (“Estimated Per Share NAV”) of $6.92 as of December 31,
2022. Shareholders should consult the REIT’s public filings pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), for any such updates, which are available at www.sec.gov.
Funding for the purchase of the Shares will
be provided through the Purchaser’s available cash on hand. The Offer is not being made for the purpose of acquiring or influencing
control of the business of the REIT. The Offer will expire at 11:59 p.m., Eastern Time on September 6, 2023, unless and until the
Purchaser, in its sole discretion, shall have extended the period of time for which the Offer is open (such date and time, as extended
the “Expiration Date”). The Purchaser will not provide a subsequent offering period following the Expiration Date. If
the Purchaser makes a material change in the terms of the Offer, or if it waives a material condition to the Offer, the Purchaser will
extend the Offer and disseminate additional tender offer materials to the extent required by Rules 14d-4(d)(1) and 14d-6(d) under
the Exchange Act. The minimum period during which the Offer must remain open following any material change in the terms of the Offer is
generally 10 business days to allow for adequate dissemination to shareholders. Accordingly, if prior to the Expiration Date, the
Purchaser increases (other than increases of not more than two percent of the outstanding Shares) or decreases the number of Shares being
sought, or increases or decreases the consideration offered pursuant to the Offer, and if the Offer is scheduled to expire at any time
earlier than the period ending on the tenth business day from the date that notice of such increase or decrease is first published, sent
or given to shareholders, the Offer will be extended at least until the expiration of such tenth business day. For purposes of the Offer,
a “business day” means any day other than a Saturday, Sunday or federal holiday and consists of the time period from 12:01
a.m. through midnight, Eastern Time. In all cases payment for the Shares purchased pursuant to the Offer will be made only after
timely receipt of the Assignment Form (or facsimile or telecopy thereof), properly completed and duly executed, with any required
signature guarantees, and any other documents required by such Assignment Form and successful transfer of ownership.
Tenders of Shares made pursuant to the Offer
are irrevocable, except that shareholders who tender their Shares in response to the Offer will have the right to withdraw their tendered
Shares at any time prior to the Expiration Date by sending to Central Trade and Transfer, LLC, an affiliate of Orchard Securities, LLC,
Member FINRA/SIPC (“CTT”), a written or facsimile transmission notice of withdrawal identifying the name of the person who
tendered Shares to be withdrawn, signed by the same persons and in the same manner as the Assignment Form tendering the Shares to
be withdrawn. If tendering shareholders tender more than the number of Shares that the Purchaser seeks to purchase pursuant to the Offer
for those Shares, the Purchaser will take into account the number of Shares so tendered and take up and pay for as nearly as may be pro
rata, disregarding fractions, according to the number of Shares tendered by each tendering shareholder during the period during which
that Offer remains open. The terms of the Offer are more fully set forth in the formal Tender Offer Documents which are available
from Purchaser at the Purchaser’s expense. The Offer contains terms and conditions and the information required by Rule 14d-6(d)(1) under
the Exchange Act which are incorporated herein by reference. The Tender Offer Documents also contain important information, including
tax information, which should be read carefully before any decision is made with respect to the Offer.
For copies of the Tender Offer Documents,
call CTT at 1-800-327-9990, make a written request addressed to 365 S. Garden Grove Lane, Suite 100, Pleasant Grove, Utah
84062, Attn: Comrit Investments 1, Limited Partnership, email to offer@cttauctions.com, or visit www.cttauctions.com/offerdisclosures.
Exhibit 107
EX-FILING FEES
Calculation of Filing Fee Tables
Schedule TO
(Rule 14d-100)
CNL HEALTHCARE
PROPERTIES, INC.
(Name of Subject Company (Issuer))
COMRIT INVESTMENTS 1, LIMITED PARTNERSHIP
COMRIT INVESTMENTS LTD.
(Bidders)
Table 1 – Transaction Valuation
| |
Transaction Valuation |
Fee Rate |
Amount of Filing Fee |
| Fees to Be Paid |
$36,168,000 |
0.00011020 |
$3,985.71 |
| Fees Previously Paid |
0 |
|
0 |
| Total Transaction Valuation |
$36,168,000 |
|
|
| Total Fees Due for Filing |
|
|
$3,985.71 |
| Total Fees Previously Paid |
|
|
0 |
| Total Fee Offsets |
|
|
0 |
| Net Fee Due |
|
|
$3,985.71 |
The Transaction Valuation is estimated solely for purposes of calculating
the filing fee. This calculation is based on the offer to purchase 8,800,000 shares of Common Stock of CNL Healthcare Properties, Inc.
at a purchase price equal to $4.11 per share in cash. The filing fee was calculated in accordance with Rule 0-11 under the Securities
Exchange Act of 1934, as amended, and Fee Rate Advisory No. 1 for Fiscal Year 2023, effective October 1, 2022, by multiplying
the transaction valuation by 0.00011020.
CNL Healthcare Properties (PK) (USOTC:CHTH)
過去 株価チャート
から 10 2024 まで 11 2024
CNL Healthcare Properties (PK) (USOTC:CHTH)
過去 株価チャート
から 11 2023 まで 11 2024
